KATANA BOYD: Open Payments
NPI 1073052296 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$456 in 24 payments from 11 companies in 2025. Trend: 2023 $1,071 · 2024 $392 · 2025 $456
Food & beverage: $456
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $221 |
| Novartis Pharmaceuticals Corporation | 2 | $42 |
| Lilly USA, LLC | 2 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Merck Sharp & Dohme LLC | 1 | $15 |
Products named: QULIPTA, LEQVIO, MOUNJARO, Kerendia, GEMTESA, Ozempic, Dexcom G6 Transmitter, Cologuard Collection Kit.
Industry payments across MO — which companies pay providers there.
